Torrent Pharmaceuticals Limited — PPTs, 22-05-2026: Investor Presentation

Torrent Pharmaceuticals has announced its audited financial results for the quarter and year ended March 31, 2026.

**Business Performance:** The company delivered robust revenue growth. For Q4 FY26, total revenues surged 42% year-over-year to 4,197 Cr. The full fiscal year 2026 also saw strong performance, with total revenues rising 21% to 13,980 Cr. India remained a significant growth engine, along with the 'Others' segment showing exceptional momentum.

**Key Financial Metrics:** Delving into segments, India revenues grew 43% in Q4 and 20% for the full year. The 'Others' segment led with a remarkable 68% growth in Q4 and 32% for FY26. The United States market experienced solid expansion, with revenues up 31% in Q4 and 24% for the year. Brazil contributed with a 30% increase in Q4 and 24% for FY26, while Germany posted steady growth of 16% in Q4 and 10% for the full year.